FDA OKs Biosimilar Treatment for Certain Breast and Stomach CancersByDecember 1st 2017The FDA has approved trastuzumab-dkst (Ogivri, Mylan GmbH) as a biosimilar to trastuzumab (Herceptin, Genentech), the first biosimilar for the treatment of certain breast and stomach cancers.